Significance of expression of miR-103a-2, miR-122, and vaspin in non-alcoholic fatty liver disease with HBV infection

doi:10.3877/cma.j.issn.1674-0785.2022.02.011

Abstract

Abstract:

Objective

To investigate the expression of microRNA (miR)-103a-2, miR-122, and (vaspin) in non-alcoholic fatty liver disease (NAFLD) combined with hepatitis B virus (HBV) infection and analyze their significance.

Methods

A total of 97 NAFLD patients with HBV infection admitted to Dongying Shengli Oilfield Central Hospital from May 2019 to May 2021 were selected as an observation group, 82 patients with simple NAFLD were selected as an NAFLD group, and another 80 healthy subjects were selected as a normal group. The relative expression levels of miR-103A-2 and miR-122 were detected by real-time fluorescence quantitative assay (qRT-PCR). Serum vaspin level was determined by enzyme-linked immunosorbent assay (ELISA). An automatic biochemical analyzer was used to determine liver function indexes [total bilirubin (TBIL), aspartate aminotransferase (AST), and alanine aminotransferase (ALT)]. The relative expression levels of miR-103A-2 and miR-122 and the changes of TBIL, AST, and ALT levels in each group were compared. Spearman analysis was used to analyze the correlation of miR-103a-2, miR-122, and vaspin expression with liver function. Multivariate logistic regression was used to analyze the influencing factors of NAFLD combined with HBV infection.

Results

The relative expression levels of miR-103a-2 and miR-122 as well as serum vaspin level were significantly higher in the observation group than in the NAFLD group and normal group (P＜0.05), and in the NAFLD group than in the normal group (P＜0.05). Serum TBIL, AST, and ALT levels were significantly higher in the observation group than in the NAFLD group and normal group (P＜0.05), and in the NAFLD group than in the normal group (P＜0.05). Spearman correlation analysis showed that miR-103a-2, miR-122, and vaspin were positively correlated with serum levels of TBIL, AST, and ALT (P＜0.05). Multivariate logistic regression analysis showed that miR-103a-2, miR-122, and vaspin were independent risk factors affecting NAFLD combined with HBV infection.

Conclusion

miR-103a-2, miR-122, and vaspin are highly expressed in NAFLD patients with HBV infection, and are independent risk factors for NAFLD with HBV infection.

Key words: MicroRNA-103a-2, MicroRNA-122, Serine protease inhibitor, Non-alcoholic fatty liver disease, Hepatitis B virus infection

Wenwen Ma, Min Hu, Guihong Wang, Jian Gao. Significance of expression of miR-103a-2, miR-122, and vaspin in non-alcoholic fatty liver disease with HBV infection[J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(02): 170-174.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2022.02.011

https://zhlcyszz.cma-cmc.com.cn/EN/Y2022/V16/I02/170

Figures/Tables 4

References 18

1	Golabi P, Rhea L, Henry L, et al. Hepatocellular carcinoma and non-alcoholic fatty liver disease [J]. Hepatol Int, 2019, 13(6): 688-694.
2	Joo EJ, Chang Y, Yeom JS, et al. Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: a cohort study [J]. Hepatology, 2017, 65(3): 828-835.
3	高金保, 刘霞. 非酒精性脂肪性肝病患者血清中循环microRNAs表达水平及意义 [J/OL]. 中国肝脏病杂志(电子版), 2014(2): 56-58.
4	章建伟, 吴若雅, 潘海滔. 青少年肥胖非酒精性脂肪肝患者血清外泌体源性miRNA表达谱的初步研究 [J]. 检验医学与临床, 2021, 18(1): 87-90.
5	佀思聪, 杨伟, 罗鸿宇, 等. Vaspin与2型糖尿病合并非酒精性脂肪性肝病的相关性分析[J]. 中国医学前沿杂志(电子版), 2019, 11(4): 70-73.
6	陆晓怡, 华国栋, 白洁, 等. 参芪扶正注射液联合索拉非尼对肝癌术后患者微小RNA-103、趋化因子受体及甲胎蛋白的影响 [J]. 中西医结合肝病杂志, 2020, 30(3): 218-220, 230
7	中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018更新版) [J]. 中华肝脏病杂志, 2018, 26(3): 195-203.
8	中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015更新版) [J]. 中华肝脏病杂志, 2015, 23(12): 888-905.
9	Zhu LG, Jiang J, Zhai XJ, et al. Hepatitis B virus infection and risk of non-alcoholic fatty liver disease: a population-based cohort study [J]. Liver Int, 2019, 39(1): 70-80.
10	牟翊瑄, 周晓琳. miRNA在非酒精性脂肪肝病中的作用研究进展 [J]. 生命的化学, 2019, 39(2): 328-332.
11	梁新妹, 梁晨, 李丹, 等. 循环血清miR-34a在非酒精性单纯性脂肪肝诊断中价值的研究进展 [J]. 中华保健医学杂志, 2020, 22(6): 666-668.
12	王鹭, 朱琳, 孙宇, 等. MicroRNA在非酒精性脂肪肝病变中的研究进展 [J]. 国际遗传学杂志, 2018, 41(3): 219-224.
13	王旭, 李丹妮, 付俣萧, 等. 血清循环miR-103a-2在非酒精性脂肪性肝病中的表达及意义 [J]. 临床检验杂志, 2017, 35(5): 346-348.
14	叶青, 赵敏, 冉紫晶, 等. miRNA-122在慢性乙型肝炎患者循环血清中的水平表达及与病情程度的相关性分析 [J]. 四川医学, 2021, 42(6): 585-590.
15	Long JK, Dai W, Zheng YW, et al. miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease [J]. Mol Med, 2019, 25(1): 26.
16	陈香梅, 张亮, 齐立明, 等. 脂肪因子Vaspin在非酒精性脂肪性肝病中的表达及其临床意义 [J]. 中国现代医学杂志, 2021, 31(6): 37-43.
17	苏秀丽, 王同生, 张英剑. 血清脂肪因子网膜蛋白-1和内脏脂肪组织来源的丝氨酸蛋白酶抑制剂在非酒精性脂肪性肝病患者中的表达及意义 [J]. 临床内科杂志, 2021, 38(2): 94-96.
18	苏秀丽, 王同生, 张英剑. 血清omentin-1和vaspin在非酒精性脂肪性肝病患者中的表达及意义 [J]. 肝脏, 2021, 26(1): 67-70.

组别	例数	miR-103a-2相对表达量	miR-122相对表达量	vaspin（ng/ml）
观察组	97	2.59±0.43^ab	5.34±0.87^ab	3.42±0.58^ab
NAFLD组	82	1.62±0.29^a	2.95±0.65^a	2.03±0.41^a
正常组	80	1.00±0.02	1.01±0.03	0.75±0.24

组别	例数	miR-103a-2相对表达量	miR-122相对表达量	vaspin（ng/ml）
观察组	97	2.59±0.43^ab	5.34±0.87^ab	3.42±0.58^ab
NAFLD组	82	1.62±0.29^a	2.95±0.65^a	2.03±0.41^a
正常组	80	1.00±0.02	1.01±0.03	0.75±0.24

组别	例数	TBIL（μmol/L）	AST（U/L）	ALT（U/L）
观察组	97	20.84±2.15^ab	83.24±8.49^ab	74.52±7.95^ab
NAFLD组	82	17.36±1.67^a	52.54±6.57^a	54.78±8.41^a
正常组	80	7.86±0.89	20.72±3.51	23.24±4.18

组别	例数	TBIL（μmol/L）	AST（U/L）	ALT（U/L）
观察组	97	20.84±2.15^ab	83.24±8.49^ab	74.52±7.95^ab
NAFLD组	82	17.36±1.67^a	52.54±6.57^a	54.78±8.41^a
正常组	80	7.86±0.89	20.72±3.51	23.24±4.18

指标	miR-103a-2		miR-122		vaspin
指标	r值	P值	r值	P值	r值	P值
TBIL	0.527	0.028	0.623	0.003	0.563	0.016
AST	0.681	＜0.001	0.725	＜0.001	0.589	0.007
ALT	0.502	0.032	0.536	0.023	0.647	0.001

Please choose a citation manager

Content to export